In a step likely to advance personalized cancer treatment, scientists have for the first time shown in patients that levels of biomarkers are not enough to tell which patients are likely to respond best to immunotherapy. Instead, clinicians need to understand how immune cells and tumors are interacting within a patient, rather than simply the levels of each associated proteins present, to prescribe the best treatment.